Lord Abbett Health Care C (LHCCX)
| Fund Assets | 8.67M |
| Expense Ratio | 1.78% |
| Min. Investment | $1,500 |
| Turnover | 91.00% |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Dividend Growth | n/a |
| Payout Frequency | n/a |
| Ex-Dividend Date | n/a |
| Previous Close | 22.86 |
| YTD Return | 7.22% |
| 1-Year Return | 33.04% |
| 5-Year Return | 21.04% |
| 52-Week Low | 17.23 |
| 52-Week High | 23.11 |
| Beta (5Y) | n/a |
| Holdings | 60 |
| Inception Date | Jul 31, 2019 |
About LHCCX
Lord Abbett Health Care Fund Class C is an actively managed mutual fund that focuses on delivering long-term capital growth by investing primarily in equities of companies within the health care sector. The fund targets a diverse array of health care industries, including pharmaceuticals, biotechnology, medical devices, and health care services, providing investors with comprehensive exposure to one of the most dynamic areas of the global economy. Since its inception in 2019, the fund has sought to capitalize on innovation and demographic trends that drive demand for health solutions. Its investment approach emphasizes identifying companies poised for growth due to advancements in science, technology, and changing health care needs. The fund plays a significant role for investors seeking sector-specific diversification, particularly those interested in benefitting from structural shifts in health care, such as aging populations and evolving medical technologies. Lord Abbett Health Care Fund Class C is structured to accommodate retail investors, offering professional management and reinvestment of distributions, while its expense structure reflects the costs associated with active sector investing.
Performance
LHCCX had a total return of 33.04% in the past year, including dividends. Since the fund's inception, the average annual return has been 9.44%.
Top 10 Holdings
38.34% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 9.06% |
| AstraZeneca PLC | AZN | 4.82% |
| Gilead Sciences, Inc. | GILD | 4.33% |
| Johnson & Johnson | JNJ | 3.25% |
| Nektar Therapeutics | NKTR | 3.23% |
| Natera, Inc. | NTRA | 2.97% |
| Tarsus Pharmaceuticals, Inc. | TARS | 2.88% |
| Guardant Health, Inc. | GH | 2.68% |
| argenx SE | ARGX | 2.61% |
| Novartis AG | NOVN | 2.52% |